Jublia sales growth
First written in FY2017-Q3. 13 of 29 entries say "Restated". Latest entry: 2026-11-09.
Kaken Pharmaceutical moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2026: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「For pharmaceuticals and medical devices, sales increased because of higher sales of エクロック and other products and the launch of エクテリー (generic name: sebetralstat), but overall sales declined as the replacement of クレナフィン with its authorized generic progressed.」
For クレナフィン, the launch of an authorized generic by 科研ファルマ and the progress of the switch to the authorized generic were explicitly identified as new factors behind the decline in sales, replacing the previous sales-growth theme. - 2026-05-13WorsenedRevisions to earnings forecasts
「加えて、国内医薬品売上の減少も影響しており、特に主力製品である「クレナフィン群」において、2025 年 9 月以降のオーソライズド・ジェネリック（AG）への移行が進んだことなどから、前期実績値との間で差異が生じる結果となりました。」
クレナフィン群の国内売上減少について、2025年9月以降のAGへの移行進展が具体的な要因として記載された。 - FY2024-Q3RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the joint-function improvement agent アルツ and the primary axillary hyperhidrosis treatment エクロック and other products increased, but sales declined because lower sales of the onychomycosis treatment クレナフィン, the absorbable adhesion barrier セプラフィルム and other products were affected by competing products, drug price revisions and other factors.」
The decline in クレナフィン sales continues to be cited as a factor behind the decline in pharmaceutical sales affected by competing products, drug price revisions and other factors. - FY2024-Q2RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the primary axillary hyperhidrosis treatment エクロック and the joint-function improvement agent アルツ and other products increased, but sales declined because lower sales of the absorbable adhesion barrier セプラフィルム, the onychomycosis treatment クレナフィン and other products were affected by competing products, drug price revisions and other factors.」
The decline in クレナフィン sales continues to be cited, together with セプラフィルム and other products, as a factor behind the decline in pharmaceutical sales resulting from competing products, drug price revisions and other factors. - FY2024-Q1Re-mentioned / Sales declineAnnual report
「Sales declined because lower sales of the absorbable adhesion barrier セプラフィルム, the onychomycosis treatment クレナフィン and other products were affected by competing products, drug price revisions and other factors.」
クレナフィン, which had been excluded from the list of main factors behind the decline in sales in the previous quarterly report, was again explicitly cited as having lower sales in the current quarter. - FY2023-Q2DroppedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ, the absorbable adhesion barrier セプラフィルム and other products.」
クレナフィン, which had been cited as a factor behind the decline in sales through the previous first quarter, was no longer included among the main factors behind the decline during the cumulative second-quarter period. - FY2023-Q1RestatedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the onychomycosis treatment クレナフィン, the joint-function improvement agent アルツ and other products.」
The decline in クレナフィン sales continues to be cited, together with アルツ and other products, as a factor behind the decline in pharmaceutical sales. - FY2022RestatedAnnual report
「For pharmaceuticals and medical devices, クレナフィン sales declined, but sales increased because of higher sales of the primary axillary hyperhidrosis treatment エクロック and generic drugs, as well as higher overseas sales resulting from growth in Jublia sales.」
The decline in クレナフィン sales continued to be reported for the full fiscal year. Meanwhile, overall pharmaceutical sales increased, helped by エクロック, generic drugs and other products, and Jublia. - FY2022-Q3RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン declined, but sales increased because of higher sales of the primary axillary hyperhidrosis treatment エクロック, the joint-function improvement agent アルツ, generic drugs and other products.」
The decline in クレナフィン sales was reported again, following the previous quarter. Overall pharmaceutical sales increased because of higher sales of エクロック, アルツ, generic drugs and other products. - FY2022-Q2SoftenedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン declined, but sales increased because of higher sales of the joint-function improvement agent アルツ, generic drugs and other products.」
Whereas the previous first quarter described sales as broadly unchanged year on year, the cumulative second-quarter period explicitly reported a decline in クレナフィン sales. The theme of クレナフィン sales growth weakened further. - FY2022-Q1SoftenedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン were broadly unchanged year on year, but sales increased because of higher sales of the joint-function improvement agent アルツ and other products.」
The description of declining クレナフィン sales in the previous fiscal year and the previous first quarter changed to broadly unchanged year on year in the current first quarter. Although sales growth was not achieved, the wording indicating a decline became less negative. - FY2021SoftenedAnnual report
「For its core product クレナフィン, domestic sales declined because of reduced patient visits to medical institutions resulting from the spread of COVID-19 and other factors」
Whereas domestic クレナフィン sales had been described as growing or increasing through the previous fiscal year, a decline in domestic sales was explicitly reported for the current fiscal year. Meanwhile, sales began in Macau and an application for approval of the new drug was accepted in China. - FY2021-Q3SoftenedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン, among other factors.」
Whereas クレナフィン sales had been described as broadly unchanged year on year in the previous quarter, a decline in sales was explicitly reported in the third quarter, further weakening the sales-growth theme. - FY2021-Q2SoftenedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン, among other factors.」
A decline in クレナフィン sales was explicitly reported again, following the previous quarter, and was a factor behind the decline in pharmaceutical sales together with アルツ. The theme of クレナフィン sales growth remains weak. - FY2021-Q1SoftenedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン, among other factors.」
Whereas クレナフィン sales had been described as broadly unchanged year on year through the previous quarter, the first quarter explicitly cited a decline in sales of both クレナフィン and アルツ, weakening the sales-growth theme. - FY2020-Q3RestatedAnnual report
「Sales of the onychomycosis treatment クレナフィン and the absorbable adhesion barrier セプラフィルム were broadly unchanged year on year, but」
クレナフィン sales were described as broadly unchanged year on year, following the previous quarter, and there is no new statement indicating an increase in sales. - FY2020-Q2RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン, the joint-function improvement agent アルツ and the absorbable adhesion barrier セプラフィルム were broadly unchanged year on year, but」
クレナフィン sales were described as broadly unchanged year on year, following the previous quarter, and there is no wording indicating an increase in sales. - FY2020-Q1SoftenedAnnual report
「Sales of the onychomycosis treatment クレナフィン and the joint-function improvement agent アルツ were broadly unchanged year on year, but」
Whereas an increase in クレナフィン sales had been reported through the previous quarter, sales were described as broadly unchanged year on year in the first quarter, weakening the wording regarding sales growth. - FY2019RestatedAnnual report
「クレナフィン sales in Japan increased, while licensing activities in overseas markets, including South Korea, Taiwan, Hong Kong, Macau and China, progressed」
Growth in domestic クレナフィン sales was confirmed for the full fiscal year. Overseas licensing activities progressed in South Korea, Taiwan, Hong Kong, Macau and China. - FY2019-Q3RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン increased, but」
The increase in クレナフィン sales was again reported, following the previous quarter. - FY2019-Q2RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン increased, but」
The increase in クレナフィン sales was again reported, following the previous quarter. - FY2019-Q1AdvancedAnnual report
「Sales of the onychomycosis treatment クレナフィン increased, but」
Whereas sales had been described as broadly unchanged year on year through the previous fiscal year, an increase in クレナフィン sales was explicitly stated for the first quarter. - FY2018RestatedAnnual report
「Sales of the onychomycosis treatment クレナフィン and the joint-function improvement agent アルツ were broadly unchanged year on year, but」
クレナフィン sales were described as broadly unchanged year on year for the full fiscal year, as in the previous quarters, and there is no new statement indicating sales growth. - FY2018-Q3RestatedAnnual report
「Sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン were broadly unchanged year on year, but」
クレナフィン sales were described as broadly unchanged year on year, as in the previous quarter, and there is no new statement indicating sales growth. - FY2018-Q2RestatedAnnual report
「Sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン were broadly unchanged year on year, but」
クレナフィン sales were described as broadly unchanged year on year, as in the previous quarterly report. アルツ was likewise described as broadly unchanged year on year. - FY2018-Q1SoftenedAnnual report
「Sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン were broadly unchanged year on year, but」
Whereas the previous filing stated that クレナフィン sales had increased, the current filing describes sales as broadly unchanged year on year, weakening the wording regarding sales growth. - FY2017-Q3First statedAnnual report
「Sales of the onychomycosis treatment クレナフィン increased」
The Company explained that クレナフィン sales increased during the nine-month period. However, overall pharmaceutical sales declined because of drug price revisions and lower income from overseas licensees.